Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.

In a Phase III trial, more patients on Scemblix had a major molecular response than on investigator-selected tyrosine kinase inhibitors.

The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.

The FDA had asked for more chemistry, manufacturing, and controls information after reviewing an earlier BLA on the investigational therapy.